HCG Healthcare Global Enterprises Q4 FY25 results (Jan–Mar 2025) and concall
Health.Global reported a strong Q4 and FY25, driven by robust growth in core and emerging centers, and strategic expansions. While PAT was impacted by increased depreciation and interest from recent investments, the company is optimistic about future growth and margin improvement, especially with new investors (KKR) and planned divestment of the Milann business.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 554 | 559 | 585 |
| EBITDA | 102 | 88 | 106 |
| Net profit | 21 | 8 | 7 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
